Target Name: MIR195
NCBI ID: G406971
Review Report on MIR195 Target / Biomarker Content of Review Report on MIR195 Target / Biomarker
MIR195
Other Name(s): hsa-miR-195-5p | hsa-mir-195 | mir-195 | MicroRNA 195 | MIRN195 | hsa-miR-195-3p | microRNA 195 | miRNA195

MIR195: A Potential Drug Target and Biomarker

MIR195 (hsa-miR-195-5p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and its potential as a drug have piqued the interest of pharmaceutical companies.

MIR195 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

One of the key features of MIR195 is its expression pattern. It is highly expressed in various tissues and cells, including the brain, heart, and cancer cells. Its expression is also regulated by various factors, including the cell cycle, apoptosis, and inflammation.

MIR195 has also been shown to play a role in the regulation of cellular processes that are relevant to several diseases, including cancer. For example, studies have shown that MIR195 can promote the growth and survival of cancer cells, and can also inhibit the anti-cancer effects of various chemotherapy drugs.

In addition to its potential as a drug target, MIR195 has also been identified as a potential biomarker for several diseases. Its expression patterns have been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of MIR195 as a drug target is its small size and non-coding nature. This makes it easier to manipulate and study than many other miRNAs. Researchers have also shown that MIR195 can be targeted to the endoplasmic reticulum (ER), which is the site of protein synthesis and degradation, making it a potential drug candidate for protein-based therapeutics.

Another potential advantage of MIR195 as a drug target is its ability to cross-talk with multiple targets. Studies have shown that MIR195 can interact with a variety of protein molecules, including transcription factors, RNA binding proteins, and metabolic enzymes. This makes it a potential drug target that can have a cascading effect on multiple cellular processes.

MIR195 has also been shown to have a negative impact on the expression of other genes. Studies have shown that MIR195 can inhibit the expression of genes that are involved in cell growth, apoptosis, and inflammation. This makes it a potential drug target that can have a positive impact on the regulation of cellular processes.

In conclusion, MIR195 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and expression pattern have made it an attractive target for researchers to study, and its potential as a drug have piqued the interest of pharmaceutical companies. Further research is needed to fully understand the role of MIR195 in cellular processes and its potential as a drug.

Protein Name: MicroRNA 195

The "MIR195 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR195 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B